SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at or listen in by dialing the U.S. toll free number (888) 800-8770 or international +1 (646) 307-1953. Conference ID: 7568777. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. 旧金山--(美国商业资讯)--Vir Biotechnology, Inc.(纳斯达克股票代码:VIR)今天宣布,该公司将于2024年10月31日提供公司最新情况并报告截至2024年9月30日的第三季度财务业绩。该公司将于2024年10月31日太平洋时间下午 1:30 /美国东部时间下午 4:30 举行电话会议。
公司最新动态和财务业绩将在市场收盘后通过新闻稿提供,并可在Vir网站投资者部分的新闻稿中查阅,网址为。参与者可以通过Vir网站活动和演示页面上的网络直播观看电话会议,也可以拨打美国免费电话(888)800-8770 或国际+1(646)307-1953收听。会议编号:7568777。电话会议的录音版本将在活动结束大约两小时后在网站上公布,并将在那里存档30天。
关于 Vir 生物技术有限公司
Vir Biotechnology, Inc. 是一家处于临床阶段的生物制药公司,致力于通过发现和开发治疗严重传染病和癌症的药物来推动免疫系统改变生活。Vir的临床阶段产品组合包括针对慢性三角型肝炎和慢性乙型肝炎感染的传染病项目,以及多个肿瘤学项目。Vir还拥有一系列针对其他传染病和肿瘤恶性肿瘤的临床前项目。Vir定期在其网站上发布可能对投资者很重要的信息。
媒体
艾伦·阿特里奇
企业传播高级副总裁
aattridge@vir.bio
投资者
理查德·莱普克
投资者关系高级董事
rlepke@vir.bio
资料来源:Vir 生物技术有限公司